[
    [
        {
            "time": "",
            "original_text": "辉瑞中国车艳：希望进博会能推动创新疫苗在中国同步上市",
            "features": {
                "keywords": [
                    "辉瑞",
                    "中国",
                    "创新疫苗",
                    "进博会",
                    "同步上市"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "辉瑞中国车艳：希望进博会能推动创新疫苗在中国同步上市",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "『医药头条君』Q4十余款新药有望获批 涉及赛诺菲、辉瑞、BMS",
            "features": {
                "keywords": [
                    "新药",
                    "获批",
                    "赛诺菲",
                    "辉瑞",
                    "BMS",
                    "Q4"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "『医药头条君』Q4十余款新药有望获批 涉及赛诺菲、辉瑞、BMS",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "693亿主力资金近三日撤出全A(等权)概念股",
            "features": {
                "keywords": [
                    "主力资金",
                    "撤出",
                    "全A",
                    "概念"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "股市"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "693亿主力资金近三日撤出全A(等权)概念股",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复星医药旗下印度 Grand Pharma 计划下月进行高达9亿美元的IPO",
            "features": {
                "keywords": [
                    "复星医药",
                    "印度",
                    "Grand Pharma",
                    "IPO",
                    "9亿美元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药旗下印度 Grand Pharma 计划下月进行高达9亿美元的IPO",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "超20家中国公司参与 涉及药物30多款 Q3授权交易特点有这些",
            "features": {
                "keywords": [
                    "中国公司",
                    "药物",
                    "授权交易",
                    "Q3"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "超20家中国公司参与 涉及药物30多款 Q3授权交易特点有这些",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "聚焦抗纤维化领域，多款治疗药有了新突破",
            "features": {
                "keywords": [
                    "抗纤维化",
                    "治疗药",
                    "新突破"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "聚焦抗纤维化领域，多款治疗药有了新突破",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业：拥抱生物医药第三次革命(下)：下篇-立潮头 基因治疗市场潜力无限",
            "features": {
                "keywords": [
                    "医药生物",
                    "基因治疗",
                    "市场潜力",
                    "第三次革命"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业：拥抱生物医药第三次革命(下)：下篇-立潮头 基因治疗市场潜力无限",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "生物医药行业深度报告：疫情、医保、集采 影响终端销售的三个关键词",
            "features": {
                "keywords": [
                    "生物医药",
                    "疫情",
                    "医保",
                    "集采",
                    "终端销售"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "生物医药行业深度报告：疫情、医保、集采 影响终端销售的三个关键词",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]